MedTrace Logo

Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

NCT04975256 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2024-12-16

No results posted yet for this study

Summary

This study will evaluate safety, tolerability, drug levels, molecular effects and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors that have a KRAS G12C mutation.

Conditions

Interventions

DRUG

MRTX849

KRAS G12C inhibitor

DRUG

BI 1701963

SOS1 Inhibitor

Sponsors & Collaborators

Principal Investigators

  • Richard Chao, MD · Mirati Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-28
Primary Completion
2022-11-02
Completion
2022-11-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04975256 on ClinicalTrials.gov